Empirical Evidence for Psychopharmacologic Treatment in Early-Onset Psychosis and Schizophrenia

Child and Adolescent Psychiatric Clinics of North America

Volumn 21, Issue 4, 2012, Pages 885-909

  Maloney, Ann E ^a   Yakutis, Lauren J ^a   Frazier, Jean A ^a  

^a University of Massachusetts   (United States)

Author keywords

Early onset schizophrenia; Psychopharmacologic treatment; Psychosis

Indexed keywords

ARIPIPRAZOLE; BENZATROPINE; CLOZAPINE; HALOPERIDOL; LOXAPINE; LOXATINE; MOLINDONE; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; THIORIDAZINE; UNCLASSIFIED DRUG; ZIPRASIDONE;

AGITATION; AGRANULOCYTOSIS; AKATHISIA; CARDIOVASCULAR RISK; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; EARLY INTERVENTION; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYNDROME; FATIGUE; HUMAN; HYPOMANIA; INSOMNIA; LONG TERM CARE; LOW DRUG DOSE; MANIA; MUSCLE HYPERTONIA; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PATIENT MONITORING; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; QT PROLONGATION; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TARDIVE DYSKINESIA; TREATMENT INDICATION; TREMOR; WEIGHT GAIN;

ADOLESCENT; AGE OF ONSET; ANTIPSYCHOTIC AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; HUMANS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 84867072299     PISSN: 10564993     EISSN: 15580490     Source Type: Journal    
DOI: 10.1016/j.chc.2012.07.011     Document Type: Review

References (121)

1. Kessler R.C., Berglund P., Demler O., et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62(6):593-602.
2. McGlashan T.H. Adolescent versus adult onset of mania. Am J Psychiatry 1988, 145(2):221-223.
3. Loranger A.W., Levine P.M. Age at onset of bipolar affective illness. Arch Gen Psychiatry 1978, 35(11):1345-1348.
4. Carlson G.A., Kashani J.H. Manic symptoms in a non-referred adolescent population. J Affect Disord 1988, 15(3):219-226.
5. Chambers W.J. Psychotic symptoms in prepubertal major depressive disorder. Arch Gen Psychiatry 1982, 39:921-927.
6. Ryan N.D., Puig-Antich J. Pharmacological treatment of adolescent psychiatric disorders. J Adolesc Health Care 1987, 8(1):137-142.
7. Kafantaris V., Coletti D.J., Dicker R., et al. Adjunctive antipsychotic treatment of adolescents with bipolar psychosis. J Am Acad Child Adolesc Psychiatry 2001, 40(12):1448-1456.
8. Schultz S.K., Miller D.D., Oliver S.E., et al. The life course of schizophrenia: age and symptom dimensions. Schizophr Res 1997, 23(1):15-23.
9. Buckley P.F., Correll C.U., Miller A.L. First-episode psychosis: a window of opportunity for best practices. CNS Spectr 2007, 12(9 Suppl 15):1-12. [discussion: 13-4]; [quiz: 15-6].
10. Frazier J.A., McClellan J., Findling R.L., et al. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics. J Am Acad Child Adolesc Psychiatry 2007, 46(8):979-988.
11. Schaeffer J.L., Ross R.G. Childhood-onset schizophrenia: premorbid and prodromal diagnostic and treatment histories. J Am Acad Child Adolesc Psychiatry 2002, 41(5):538-545.
12. Sikich L. Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders. J Clin Psychiatry 2008, 69(Suppl 4):21-25.
13. Werry J.S. Child and adolescent (early onset) schizophrenia: a review in light of DSM-III-R. J Autism Dev Disord 1992, 22(4):601-624.
14. American Academy of Child and Adolescent Psychiatry AACAP official action. Summary of the practice parameters for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2000, 39(12):1580-1582.
15. David C.N., Greenstein D., Clasen L., et al. Childhood onset schizophrenia: high rate of visual hallucinations. J Am Acad Child Adolesc Psychiatry 2011, 50(7):681-686 e3.
16. Russell A.T. The clinical presentation of childhood-onset schizophrenia. Schizophr Bull 1994, 20(4):631-646.
17. Rapoport J.L., Addington A., Frangou S. The neurodevelopmental model of schizophrenia: what can very early onset cases tell us?. Curr Psychiatry Rep 2005, 7(2):81-82.
18. Frazier J.A., Giuliano A.J., Johnson J.L., et al. Neurocognitive outcomes in the treatment of early-onset schizophrenia spectrum disorders study. J Am Acad Child Adolesc Psychiatry 2012, 51(5):496-505.
19. Bearden C.E., Wu K.N., Caplan R., et al. Thought disorder and communication deviance as predictors of outcome in youth at clinical high risk for psychosis. J Am Acad Child Adolesc Psychiatry 2011, 50(7):669-680.
20. Asarnow J.R., Tompson M.C., McGrath E.P. Annotation: childhood-onset schizophrenia: clinical and treatment issues. J Child Psychol Psychiatry 2004, 45(2):180-194.
21. Hooper S.R., Giuliano A.J., Youngstrom E.A., et al. Neurocognition in early-onset schizophrenia and schizoaffective disorders. J Am Acad Child Adolesc Psychiatry 2010, 49(1):52-60.
22. Oie M.R., Rund B.R. Neuropsychological deficits in adolescent-onset schizophrenia compared with attention deficit hyperactivity disorder. Am J Psychiatry 1999, 156:1216-1222.
23. Hafner H., Nowotny B. Epidemiology of early-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci 1995, 245:80-92.
24. Maziade M., Bouchard S., Gingras N., et al. Long-term stability of diagnosis and symptom dimensions in a systematic sample of patients with onset of schizophrenia in childhood and early adolescence. II: postnegative distinction and childhood predictors of adult outcome. Br J Psychiatry 1996, 169(3):371-378.
25. Thomsen P.H. Schizophrenia with childhood and adolescent onset-a nationwide register-based study. Acta Psychiatr Scand 1996, 94(3):187-193.
26. Schimmelmann B.G., Conus P., Cotton S., et al. Pre-treatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patients. Schizophr Res 2007, 95(1-3):1-8.
27. Luoma S., Hakko H., Ollinen T., et al. Association between age at onset and clinical features of schizophrenia: the Northern Finland 1966 birth cohort study. Eur Psychiatry 2008, 23(5):331-335.
28. Bellino S., Rocca P., Patria L., et al. Relationships of age at onset with clinical features and cognitive functions in a sample of schizophrenia patients. J Clin Psychiatry 2004, 65(7):908-914.
29. Frazier J.A., Alaghband-Rad J., Jacobsen L., et al. Pubertal development and onset of psychosis in childhood onset schizophrenia. Psychiatry Res 1997, 70(1):1-7.
30. Hogan M., Adams J., Arrendonodo R., et al. Achieving the promise: transforming mental health care in America 2003, Government Printing Press, Rockville (MD).
31. Newcomer J.W., Hennekens C.H. Severe mental illness and risk of cardiovascular disease. JAMA 2007, 298(15):1794-1796.
32. Kaufman J., Birmaher B., Brent D., et al. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997, 36(7):980-988.
33. Freudenreich O., Charles Schulz S., Goff D.C. Initial medical work-up of first-episode psychosis: a conceptual review. Early Interv Psychiatry 2009, 3(1):10-18.
34. Compton M.T., Kelley M.E., Ramsay C.E., et al. Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. Am J Psychiatry 2009, 166(11):1251-1257.
35. Arendt M., Rosenberg R., Foldager L., et al. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry 2005, 187(6):510-515.
36. Amar M., Potvin S. Cannabis and psychosis: what is the link?. J Psychoactive Drugs 2007, 39:131-142.
37. Gonzalez-Pinto A., Alberich S., Barbeito S., et al. Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophr Bull 2011, 37(3):631-639.
38. Schimmelmann B.G., Conus P., Cotton S., et al. Prevalence and impact of cannabis use disorders in adolescents with early onset first episode psychosis. Eur Psychiatry 2012, 27(6):463-469.
39. Schimmelmann B.G., Conus P., Cotton S.M., et al. Cannabis use disorder and age at onset of psychosis-a study in first-episode patients. Schizophr Res 2011, 129(1):52-56.
40. Kumra S. Schizophrenia and cannabis use. Minn Med 2007, 90(1):36-38.
41. Lehman A.F., Lieberman J.A., Dixon L.B., et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004, 161(Suppl 2):1-56.
42. Masi G., Liboni F. Management of schizophrenia in children and adolescents: focus on pharmacotherapy. Drugs 2011, 71(2):179-208.
43. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:262-276.
44. Andreasen N. The scale for the Assessment of Positive Symptoms (SAPS) 1984, The University of Iowa Press, Iowa (IA).
45. Andreasen N. Scale for the Assessment of Negative Symptoms (SANS) 1983, The University of Iowa Press, Iowa (IA).
46. Rush J. Psychiatric measures. Clinical Global Impressions (CGI) Scale 2000, APA, Washington, DC. W. Guy (Ed.).
47. Kryzhanovskaya L., Schulz S.C., McDougle C., et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009, 48(1):60-70.
48. Pool D., Bloom W., Mielke D.H., et al. A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Curr Ther Res Clin Exp 1976, 19(1):99-104.
49. Spencer E.K., Kafantaris V., Padron-Gayol M., et al. Haloperidol in schizophrenic children: early findings from a study in progress. Psychopharmacol Bull 1992, 28:183-186.
50. Realmuto G.M., Erickson W.D., Yellin A.M., et al. Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. Am J Psychiatry 1984, 141:440-442.
51. Correll C.U., Leucht S., Kane J.M. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004, 161(3):414-425.
52. Frazier J.A., Gordon C.T., McKenna K., et al. An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1994, 33(5):658-663.
53. Kumra S., Frazier J.A., Jacobsen L., et al. Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996, 53:1090-1097.
54. Shaw P., Sporn A., Gogtay N., et al. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 2006, 63(7):721-730.
55. Kumra S., Kranzler H., Gerbino-Rosen G., et al. Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study. J Child Adolesc Psychopharmacol 2008, 18(4):307-316.
56. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull 1988, 24:97-99.
57. Kumra S., Kranzler H., Gerbino-Rosen G., et al. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry 2008, 63(5):524-529.
58. Kim Y., Kim B.N., Cho S.C., et al. Long-term sustained benefits of clozapine treatment in refractory early onset schizophrenia: a retrospective study in Korean children and adolescents. Hum Psychopharmacol 2008, 23(8):715-722.
59. Sporn A., Gogtay N., Ortiz-Aguayo R., et al. Clozapine-induced neutropenia in children: management with lithium carbonate. J Child Adolesc Psychopharmacol 2003, 13(3):401-404.
60. Alvir J.M., Lieberman J.A. Agranulocytosis: incidence and risk factors. J Clin Psychiatry 1994, 55(Suppl B):137-138.
61. Wehmeier P.M., Heiser P., Remschmidt H. Pancreatitis followed by pericardial effusion in an adolescent treated with clozapine. J Clin Psychopharmacol 2003, 23(1):102-103.
62. Findling R.L., Frazier J.A., Gerbino-Rosen G., et al. Is there a role for clozapine in the treatment of children and adolescents?. J Am Acad Child Adolesc Psychiatry 2007, 46(3):423-428.
63. Maloney A.E., Sikich L. Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients. Neuropsychiatr Dis Treat 2010, 6:749-766.
64. Overall J., Pfefferbaum B. The brief psychiatric rating scale for children. Psychol Bull 1982, 18(2):10-16.
65. Sikich L., Hamer R.M., Bashford R.A., et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004, 29(1):133-145.
66. Correll C.U., Manu P., Olshanskiy V., et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009, 302(16):1765-1773.
67. Dittmann R.W., Meyer E., Freisleder F.J., et al. Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study. J Child Adolesc Psychopharmacol 2008, 18:54-69.
68. Aichhorn W., Marksteiner J., Walch T., et al. Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents. J Child Adolesc Psychopharmacol 2007, 17(5):665-674.
69. Armenteros J.L., Whitaker A.H., Welikson M., et al. Risperidone in adolescents with schizophrenia: an open pilot study. J Am Acad Child Adolesc Psychiatry 1997, 36(5):694-700.
70. Pandina G., Kushner S., Karcher K., et al. An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia. Child Adolesc Psychiatry Ment Health 2012, 6(1):23.
71. Holzer L., Eap C.B. Risperidone-induced symptomatic hyperprolactinaemia in adolescents. J Clin Psychopharmacol 2006, 26(2):167-171.
72. Schimmelmann B.G., Mehler-Wex C., Lambert M., et al. A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders. J Child Adolesc Psychopharmacol 2007, 17(6):768-778.
73. McConville B., Carrero L., Sweitzer D., et al. Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial. J Child Adolesc Psychopharmacol 2003, 13(1):75-82.
74. McConville B.J., Arvanitis L.A., Thyrum P.T., et al. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 2000, 61(4):252-260.
75. AstraZeneca Quetiapine fumarate (SEROQUEL) compared to placebo in the treatment of adolescent patients with schizophrenia (ANCHOR 112). ClinicalTrials.gov [Internet] 2000, National Library of Medicine (US), Bethesda (MD), Accessed July 12, 2012. Available at:, NLM Identifier: NCT00090324. http://clinicaltrials.gov/ct2/show/NCT00090324.
76. Ambler D., Maloney A., Hunt-Harrison T., et al. Ziprasidone in early onset schizophrenia and schizoaffective disorder. Biol Psychiatry 2006, 59(Suppl 8):1s-264s.
77. Patel N.C., Sierk P., Dorson P.G., et al. Experience with ziprasidone. J Am Acad Child Adolesc Psychiatry 2002, 41(5):495.
78. Findling R.L., Robb A., Nyilas M., et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008, 165(11):1432-1441.
79. Bachmann C.J., Lehr D., Theisen F.M., et al. Aripiprazole as an adjunct to clozapine therapy in adolescents with early-onset schizophrenia: a retrospective chart review. Pharmacopsychiatry 2009, 42(4):153-157.
80. Singh J., Robb A., Vijapurkar U., et al. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry 2011, 70(12):1179-1187.
81. McClellan J., Sikich L., Findling R.L., et al. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry 2007, 46(8):969-978.
82. Stroup T.S., Lieberman J.A., McEvoy J.P., et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006, 163(4):611-622.
83. Sikich L., Frazier J.A., McClellan J., et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008, 165(11):1420-1431.
84. Findling R.L., Johnson J.L., McClellan J., et al. Double-blind maintenance safety and effectiveness findings from the treatment of early-onset schizophrenia spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry 2010, 49(6):583-594.
85. White T., Ho B.C., Ward J., et al. Neuropsychological performance in first-episode adolescents with schizophrenia: a comparison with first-episode adults and adolescent control subjects. Biol Psychiatry 2006, 60(5):463-471.
86. Goldberg T.E., Keefe R.S., Goldman R.S., et al. Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology 2010, 35(5):1053-1062.
87. Remschmidt H., Martin M., Fleischhaker C., et al. Forty-two-years later: the outcome of childhood-onset schizophrenia. J Neural Transm 2007, 114(4):505-512.
88. Castro-Fornieles J., Parellada M., Gonzalez-Pinto A., et al. The child and adolescent first-episode psychosis study (CAFEPS): design and baseline results. Schizophr Res 2007, 91(1-3):226-237.
89. Rani F., Murray M.L., Byrne P.J., et al. Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 2008, 121(5):1002-1009.
90. Correll C.U., Penzner J.B., Parikh U.H., et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin North Am 2006, 15(1):177-206.
91. Correll C.U., Carlson H.E. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006, 45(7):771-791.
92. Schimmelmann B.G., Paulus S., Schacht M., et al. Subjective distress related to side effects and subjective well-being in first admitted adolescents with early-onset psychosis treated with atypical antipsychotics. J Child Adolesc Psychopharmacol 2005, 15(2):249-258.
93. Ratzoni G., Gothelf D., Brand-Gothelf A., et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry 2002, 41(3):337-343.
94. Klein D.J., Cottingham E.M., Sorter M., et al. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006, 163(12):2072-2079.
95. Klein D.J., Cottingham E.M., Sorter M., et al. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006, 163(12):2072-2079.
96. Shin L., Bregman H., Breeze J.L., et al. Metformin for weight control in pediatric patients on atypical antipsychotic medication. J Child Adolesc Psychopharmacol 2009, 19(3):275-279.
97. National High Blood Pressure Education Program Working Group on High Blood Pressure in C, Adolescents The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004, 114(2 Suppl 4th Report):555-576.
98. Abnormal involuntary movement scale (AIMS). Psychopharmacol Bull 1988, 24(4):781-783.
99. Olfson M., Blanco C., Liu L., et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006, 63(6):679-685.
100. Fisher M., Holland C., Merzenich M.M., et al. Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. Am J Psychiatry 2009, 166(7):805-811.
101. Gard D.E., Fisher M., Garrett C., et al. Motivation and its relationship to neurocognition, social cognition, and functional outcome in schizophrenia. Schizophr Res 2009, 115(1):74-81.
102. Subramaniam K., Luks Tracy L., Fisher M., et al. Computerized cognitive training restores neural activity within the reality monitoring network in schizophrenia. Neuron 2012, 73(4):842-853.
103. Wykes T., Huddy V., Cellard C., et al. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry 2011, 168(5):472-485.
104. Wolpert A., Hagamen M.B., Merlis S. A comparative study of thiothixene and trifluoperazine in childhood schizophrenia. Curr Ther Res Clin Exp 1967, 9(9):482-485.
105. Waizer J., Polizos P., Hoffman S.P., et al. A single-blind evaluation of thiothixene with outpatient schizophrenic children. J Autism Child Schizophr 1972, 2(4):378-386.
106. Engelhardt D.M., Polizos P., Waizer J., et al. A double-blind comparison of fluphenazine and haloperidol in outpatient schizophrenic children. J Autism Child Schizophr 1973, 3(2):128-137.
107. Turetz M., Mozes T., Toren P., et al. An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia. Br J Psychiatry 1997, 170:507-510.
108. Kumra S., Jacobsen L., Lenane M., et al. Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry 1998, 37(4):377-385.
109. Sholevar E.H., Baron D.A., Hardie T.L. Treatment of childhood-onset schizophrenia with olanzapine. J Child Adolesc Psychopharmacol 2000, 10(2):69-78.
110. Findling R., McNamara J., Youngstrom E., et al. A prospective, open-label trial of olanzapine in adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2003, 42(2):170-175.
111. Woods S.W., Breier A., Zipursky R.B., et al. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry 2003, 54(4):453-464.
112. Mozes T., Ebert T., Michal S.E., et al. An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia. J Child Adolesc Psychopharmacol 2006, 16(4):393-403.
113. Quintana H., Wilson M.S., Purnell W., et al. An open-label study of olanzapine in children and adolescents with schizophrenia. J Psychiatr Pract 2007, 13(2):86-96.
114. Fleischhaker C., Heiser P., Hennighausen K., et al. Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. J Neural Transm 2007, 114(2):273-280.
115. Berger G.E., Proffitt T.M., McConchie M., et al. Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years. J Clin Psychiatry 2008, 69(11):1702-1714.
116. DelBello M.P., Versavel M., Ice K., et al. Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder. J Child Adolesc Psychopharmacol 2008, 18(5):491-499.
117. Jensen J.B., Kumra S., Leitten W., et al. A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders. J Child Adolesc Psychopharmacol 2008, 18(4):317-326.
118. Haas M., Unis A.S., Armenteros J., et al. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 2009, 19(6):611-621.
119. Haas M., Eerdekens M., Kushner S., et al. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry 2009, 194(2):158-164.
120. Kryzhanovskaya L.A., Robertson-Plouch C.K., Xu W., et al. The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials. J Clin Psychiatry 2009, 70(2):247-258.
121. Arango C., Robles O., Parellada M., et al. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry 2009, 18(7):418-428.